A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is a prevalent and deadly malignancy.
• EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective against activated EGFR mutations but resistance, particularly T790M mutations, limits long-term treatment success.

Purpose of the Study:

• To investigate the efficacy of a novel small-molecule compound, D6, in overcoming EGFR-TKI resistance in NSCLC harboring T790M-EGFR mutations.
• To elucidate the mechanism of action of D6 in targeting resistant NSCLC cells.

Main Methods:

• D6, a compound derived from Codonopsis pilosula, was tested against NSCLC cell lines with various EGFR-T790M mutations.
• The study examined D6's interaction with HSP90 and its effect on T790M-EGFR degradation.
• Combination therapy with D6 and existing EGFR-TKIs (erlotinib, osimertinib) was evaluated.

Main Results:

• D6 selectively inhibited tumor cell growth and migration in NSCLC cells with T790M-EGFR mutations.
• D6 facilitates the ubiquitination and proteasomal degradation of T790M-EGFR by binding to HSP90.
• D6 demonstrated low systemic toxicity by minimally impacting normal HSP90 chaperone activity.
• Combined treatment with D6 and erlotinib or osimertinib effectively overcame EGFR-TKI resistance in NSCLC models.

Conclusions:

• D6 represents a novel therapeutic strategy for overcoming T790M-mediated EGFR-TKI resistance in NSCLC.
• Targeting the protein-protein interaction between HSP90 and T790M-EGFR with D6 offers a new avenue for NSCLC treatment.